retatrutide phase 2 trial obesity nejm 2023 Research Guide: What the Data Reported (2026) The trial that put “24%”

Discuss with your prescriber before any significant trip particularly if you're still in dose escalation

Safety profile Retatrutides most common side effects match what patients experience on semaglutide and tirzepatide: nausea, diarrhea, vomiting, and constipation

Management strategies are largely extrapolated from experience with existing GLP-1 receptor agonists, such as semaglutide and liraglutide, which are licensed and available in the UK

The combination of a credible management team, differentiated pipeline, and a proven commercial template made Kailera an unusually compelling Series B and IPO candidate

Here are three nutrition trends that I believe every cardiometabolic dietitian should have on their radar in 2026, and why they matter for clinical practice

Some experience positive psychological effects: increased confidence, reduced shame, greater social comfort